Clinical Trial Update: Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study [Phase 2]

View source ↗

Summary

Phase 2 trial update of ranibizumab for pigment epithelium tears associated with age-related macular degeneration; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: University Hospital, Bonn | Conditions: Age Related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2019-08-15